ProQR Therapeutics (NASDAQ:PRQR) Upgraded to "Buy" at Citigroup

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was upgraded by investment analysts at Citigroup from a "neutral" rating to a "buy" rating in a research note issued on Monday, Marketbeat Ratings reports. The brokerage presently has a $4.00 price target on the biopharmaceutical company's stock. Citigroup's price target points to a potential upside of 129.89% from the stock's previous close.

Several other equities research analysts have also issued reports on PRQR. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com lowered shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, November 28th. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. JMP Securities reaffirmed a "market outperform" rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ProQR Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.17.

Remove Ads

ProQR Therapeutics Trading Down 5.9 %

NASDAQ PRQR traded down $0.11 during trading on Monday, reaching $1.74. The company's stock had a trading volume of 432,130 shares, compared to its average volume of 358,682. The stock has a market capitalization of $142.12 million, a PE ratio of -5.44 and a beta of 0.24. The business has a 50-day moving average price of $2.29 and a 200-day moving average price of $2.62. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. As a group, analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Jane Street Group LLC acquired a new position in ProQR Therapeutics during the 4th quarter worth about $30,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter worth about $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics during the 4th quarter worth about $39,000. Two Sigma Securities LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $54,000. Institutional investors and hedge funds own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).